CytoSorbents Corp (CTSO)
1.50
+0.08
(+5.63%)
USD |
NASDAQ |
Sep 27, 16:00
1.48
-0.02
(-1.33%)
After-Hours: 20:00
CytoSorbents Research and Development Expense (Annual): 15.73M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.73M |
| December 31, 2022 | 15.12M |
| December 31, 2021 | 16.38M |
| December 31, 2020 | 8.811M |
| December 31, 2019 | 12.09M |
| December 31, 2018 | 7.723M |
| December 31, 2017 | 3.221M |
| December 31, 2016 | 4.073M |
| December 31, 2015 | 3.871M |
| Date | Value |
|---|---|
| December 31, 2014 | 2.432M |
| December 31, 2013 | 1.739M |
| December 31, 2012 | 2.532M |
| December 31, 2011 | 2.888M |
| December 31, 2010 | 1.757M |
| December 31, 2009 | 1.962M |
| December 31, 2008 | 1.984M |
| December 31, 2007 | 1.416M |
| December 31, 2006 | 1.113M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.811M
Minimum
2020
16.38M
Maximum
2021
13.63M
Average
15.12M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Delcath Systems Inc | 17.50M |
| Star Equity Holdings Inc | -- |
| Exact Sciences Corp | 425.88M |
| Illumina Inc | 1.354B |
| Progyny Inc | -- |